“Healthy donor cells from the hematopoietic graft migrate to the injured skin; simultaneously, there is an increase in the production of collagen type VII, increased skin integrity, and reduced tendency to blister formation.”

Tolar J, Blazar BR, Wagner JE. 

Published in:

Stem Cells. 2011 Jun;29(6):900

http://www.ncbi.nlm.nih.gov/pubmed/21557391

Zhao y. et al 2012 BMC Med. 10;10(1):3

“Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks”

http://www.biomedcentral.com/content/pdf/1741-7015-10-3.pdf

The Company’s  provides  processing and cryopreservation of Adipose Derived Stem Cells  and Adipose Tissue  for autologous use.

        American CryoStem Corporation
               Red Bank, NJ USA

http://www.americancryostem.com/

The ALS Phase I/II human clinical trial is being performed at Hadassah Medical Center in Israel in collaboration with BrainStorm and is utilizing BrainStorm’s NurOwn™ technology for growing and modifying autologous adult human stem cells to treat ALS, often referred to as Lou Gehrig’s Disease. The study is headed by Prof. Karussis, M.D., Ph.D

http://www.brainstorm-cell.com/Index.asp?ArticleID=260&CategoryID=76&Page=1

“Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children”

Acquired sensorineural hearing loss i children will be treated with autologous cord blood cells. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes are improved following hUCB treatment in this patient population.

http://clinicaltrials.gov/ct2/show/NCT01343394?term=hearing+loss+cord+blood+stem+cells&rank=1

Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon

BMC Medicine 2012, 10:3  http://www.biomedcentral.com/1741-7015/10/3/abstract

“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them to the patient’s circulation. In an open-label, phase1/phase 2 study, patients (n = 15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years (range, 15 to 41), and median diabetic history was 8 years (range, 1 to 21).”

Stem Cell Educator therapy was well tolerated and can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks.

Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S; Japanese Cord Blood Bank Network.

Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.

“Umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between 1998 and 2008 in Japan; severe combined immunodeficiency (SCID, n = 40), Wiskott-Aldrich syndrome (WAS, n = 23), chronic granulomatous disease (n = 7), severe congenital neutropaenia (SCN, n = 5) and other immunodeficiencies (n = 13). Five-year overall survival (5-year OS) for all patients was 69% [95% confidence interval (CI), 57-78%], and was 71% and 82% for SCID and WAS, respectively. The main cause of death before day 100 was infection (17/19), while that after day 100 was graft-versus-host disease (GVHD) (5/7). We conclude that UCBT should be considered for PID patients without an HLA-matched sibling. The control of pre-transplant infection and selection of HLA-matched donors will lead to a better outcome”

Published in: Br J Haematol. 2011 154:363-72

Adoptive cell therapy is provided as experimental treatment for metastatic melanoma patients at the Ella Institute, the Sheba Medical Center, Israel.

Along with other advanced technologies, eligible patients are offered the advanced immunotherapy treatment with TIL (tumor infiltrating lymphocytes).This treatment was developed at the National Institute of Health, US, and very encouraging clinical results have been published by both institutions in the US and Israel*.

*

1. Clin Cancer Res. 2011 17:4550-7.

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.

2. Clin Cancer Res. 2010 16:2646-55.

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J

Presentation by Dr. Joanne Kurtzberg

http://ash.eventmediasite.com/media/127_3/index.htm

]]> http://mynewtherapy.com/cord-blood-transplantation-for-neurological-diseases/feed/ 0 http://mynewtherapy.com/bone-marrow-transplant-compared-to-mobilized-peripheral-blood/ http://mynewtherapy.com/bone-marrow-transplant-compared-to-mobilized-peripheral-blood/#comments Mon, 12 Dec 2011 17:52:30 +0000 New Therapy Expert http://mynewtherapy.com/?p=2386 A new study finds that mobilized peripheral blood stem cells convey no survival advantage over bone marrow transplants when the donor is not an HLA-identical sibling of the recipient. 

Interview at the annual meeting of the American Society of Hematology –  December 2011 

http://www.youtube.com/watch?v=jHfCqV4Xt4s

“Two-year overall survival among 273 patients randomized to receive filgrastim (Neupogen)-mobilized peripheral blood stem cells (PBSC) from an unrelated donor was 51% in an intention-to-treat analysis, compared with 46% of 278 patients randomized to bone-marrow transplants (BMT), also from an unrelated donor”

http://www.oncologyreport.com/news/clinical/single-article/pbsc-transplants-from-unrelated-donors-show-no-survival-advantage/c85ea16df6.html